1 active not recruiting, 1 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow C3 Glomerulonephritis: new trials by email Literature Review of C3 Glomerulonephritis trials Research Report on C3 Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
Glomerulonephritis, Membranoproliferative (2)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2)
pegcetacoplan (2)
Apellis Pharmaceuticals, Inc. (2)
Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Czechia (2) · France (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2) · South Korea (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · United States (2)
2023 (1)